Evaluation of anti-inflammatory, immunomodulatory effects and celiac-like side effect of olmesartan medoxomil as a vitamin D receptor agonist and angiotensin II receptor blocker

Basit Öğe Kaydı
dc.contributor.authorKarasulu, Ercüment
dc.date.accessioned2022-04-21T08:35:24Z
dc.date.available2022-04-21T08:35:24Z
dc.date.issued2022en_US
dc.departmentFakülteler, Eczacılık Teknolojisi Bilimleri Bölümü, Farmasötik Teknoloji Ana Bilim Dalıen_US
dc.description.abstractProdrug Olmesartan Medoxomil (OM) is an angiotensin II receptor blocker (ARB) and a vitamin D Receptor (VDR) agonist. Reducing the inflammation and improving the immune system OM prevents organ damage. Angiotensin II receptor blockers (ARBs) can raise serum and tissue levels of the membrane-bound form of monocarboxypeptidase angiotensin converting enzyme 2 (ACE2). Increased ACE2 activity causes the balance in the RAAS to shift towards the positive ACE2-Ang-(1-7). Therefore It can be useful with anti-inflammatory, anti-fibrotic and anti-oxidative stress signals in the treatment of immune system diseases. OM is also known to have adverse effects, such as celiac-like enteropathy which was accepted by the FDA. The mechanism of OM's intestinal injury is thought to be the excessive consumption of the enzymes POX1 and carboxymethylenebutenolidase, which are also responsible for the the digestion of gliadin during the hydrolysis of the drug. Cell-mediated immune response and genetic predisposition are the other factors. Our histopathological findings of olmesartan-induced celiac-like enteropathy in rat intestines were increased mononuclear cell infiltration and villous atrophy. In this study these various action mechanisms of OM and its possible immun system booster effects were discussed. The findings of our rat intestines after exposure to OM-Suspension supported and correlated clinical findings of OM. In conclusion, by making extensive evaluations, OM can be a promising immunomodulator agent in immune system diseases.en_US
dc.identifier.citationKömesli, Y., & Karasulu, E. (2022). Evaluation of anti-inflammatory, immunomodulatory effects and celiac-like side effect of olmesartan medoxomil as a vitamin D receptor agonist and angiotensin II receptor blocker. Journal of Research in Pharmacy, 26(1), 63-74.en_US
dc.identifier.endpage74en_US
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85127048568
dc.identifier.scopusqualityQ3
dc.identifier.startpage63en_US
dc.identifier.trdizinid520447
dc.identifier.urihttps://hdl.handle.net/20.500.12939/2358
dc.identifier.volume26en_US
dc.identifier.wosWOS:000738259100008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorKömesli, Yelda
dc.language.isoen
dc.publisherJournal of Research in Pharmacyen_US
dc.relation.ispartofJournal of Research in Pharmacy
dc.relation.isversionof10.29228/jrp.104en_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectARBen_US
dc.subjectVitamin-Den_US
dc.subjectVDR-Agonisten_US
dc.subjectACE2en_US
dc.subjectAng-(1-7)en_US
dc.subjectPON1en_US
dc.subjectCeliac-Like-Enteropathyen_US
dc.subjectImmunotherapeuticen_US
dc.titleEvaluation of anti-inflammatory, immunomodulatory effects and celiac-like side effect of olmesartan medoxomil as a vitamin D receptor agonist and angiotensin II receptor blocker
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
pdf_MPJ_968.pdf
Boyut:
836.62 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Eczacılık Fakültesi Yayın Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu